Twist Bioscience Acquires Genome Compiler To Add Gene Design Capabilities
SAN FRANCISCO and TEL AVIV, Israel, April 6, 2016 /PRNewswire/ -- Twist Bioscience Corporation, a company accelerating science and innovation through rapid, high-quality DNA synthesis, today announced the acquisition of Genome Compiler Corporation, an Israeli-based company providing software for genetic engineers, molecular and synthetic biologists. Twist Bioscience intends to leverage Genome Compiler's technology and expertise to drive a digital products portfolio, including an eCommerce solution with gene design capabilities, expected to be available in the second half of 2016.
"Twist's beta program is progressing well and our first customer shipments are underway," said Emily M. Leproust, Ph.D., CEO of Twist Bioscience. "Over the next few months we expect to scale our gene volume substantially, enabling us to offer market-leading production levels by this summer. We are delighted to bring the Genome Compiler technology, network and expert team into the Twist Bioscience organization. They are the leader in developing software that allows design of gene sequences for synthetic and molecular biology experiments. We intend to build an elegant, intuitive eCommerce solution with a deep pipeline of digital products to follow that will enable our customers to reimagine their research by providing seamless integration of the design and build of their synthetic DNA."
Under the terms of the agreement, the Genome Compiler research and development center in Israel will become Twist Bioscience's first international site. Twist Bioscience intends to expand the center in Tel Aviv to advance its digital product and gene design capabilities. Financial terms of the deal were not disclosed.
"We are extremely excited to join forces with Twist Bioscience," commented Omri Amirav-Drory, Ph.D., founder and CEO of Genome Compiler. "By combining our advanced software design capabilities with the technology leader in DNA synthesis, our customers will be able to streamline the design-build-test cycle. We believe the synthetic and molecular biology communities will find the integrated offering a great platform to accelerate their research."
About Twist Bioscience Corporation
At Twist Bioscience, our expertise is accelerating science and innovation by leveraging the power of scale. We have developed a proprietary semiconductor-based synthetic DNA manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools, including genes, oligonucleotide pools and variant libraries. By synthesizing DNA on silicon instead of on traditional 96-well plastic plates, our platform overcomes the current inefficiencies of synthetic DNA production, and enables cost-effective, rapid, high-quality and high throughput synthetic gene production, which in turn, expedites the design, build, test cycle to enable personalized medicines, pharmaceuticals, sustainable chemical production, improved agriculture production, diagnostics, biodetection and data storage. For more information, please visit www.twistbioscience.com. Twist Bioscience is on Twitter. Sign up to follow our Twitter feed @TwistBioscience at https://twitter.com/TwistBioscience.
About Genome Compiler Corporation
Genome Compiler provides an intuitive all-in-one software platform for genetic engineers, molecular and synthetic biologists. The company supplies a comprehensive set of tools for DNA design & visualization, data management and collaboration. Using Genome Compiler, customers benefit from an optimal design experience with its extensive suite of advanced design tools, a variety of plasmids and parts repositories, direct connections to an array of DNA synthesis providers and lab automation services, all in one platform. Genome Compiler was incubated at Singularity University Labs and participated in the S15 class of the NFX Guild incubator and raised $6M from Autodesk, LionBird VC and angel investors.
Logo - http://photos.prnewswire.com/prnh/20140526/91128
Logo - http://photos.prnewswire.com/prnh/20160401/350665LOGO
Share this article